ArticleBMC biotechnology2025
Biomimetic nanoparticles coated with ScFv-modified macrophage membranes for siRNA delivery to relieve brain metastases of lung cancer.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn China, lung cancer stands as the leading cause of cancer-related deaths, often resulting in brain metastases (BM) that severely compromise patients' quality of life and reduce survival outcomes. The delivery of drugs to the brain is further complicated by the blood-brain barrier (BBB). To address this, we developed EGFR single-chain fragment variable (scFv)-modified macrophage membrane liposomes (scFv-MML) encapsulating LPCAT1 siRNA (scFv-MML@LPCAT1si) as a targeted therapy for non-small cell lung cancer (NSCLC) BM.
methodsEGFR scFv-pcDNA3.1(-) plasmids were transfected into RAW 264.7 cells to generate RAW 264.7-scFv cells. Macrophage membranes were isolated from these cells and used to coat liposomes (Lip) encapsulating LPCAT1 siRNA via extrusion. The cellular uptake, LPCAT1 silencing, and anti-tumor efficacy of scFv-MML@LPCAT1si were evaluated in vitro using PC9 lung cancer cells. In vivo studies were performed in a mouse model of NSCLC BM to assess tumor targeting, accumulation, and therapeutic effects.
resultsIn vitro, scFv-MML@LPCAT1si exhibited superior cellular uptake and silencing of LPCAT1 expression in EGFR-positive PC9 cells compared to control liposomes, leading to increased cell apoptosis and decreased proliferation. In vivo, scFv-MML@LPCAT1si showed improved tumor targeting and accumulation in the brain, effectively slowing tumor growth and reducing body weight loss in mice with NSCLC BM. The biodistribution study revealed sustained tumor fluorescence intensity for more than 24 h after injection, with significant retention of siRNA within the tumor site. No significant systemic toxicity or organ damage was observed in mice treated with scFv-MML@LPCAT1si.
conclusionsOur findings suggest that scFv-MML@LPCAT1si represents a promising targeted therapy for NSCLC BM, leveraging the unique properties of scFv-MML to traverse the BBB and deliver therapeutic payloads to tumor sites with high accuracy and efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.